FDA authorizes first next generation sequencing-based test to detect very low levels of remaining cancer cells in patients with acute lymphoblastic leukaemia or multiple myeloma

28 September 2018 - Today the U.S. FDA permitted marketing of ClonoSEQ assay, a next generation sequencing-based test for minimal residual ...

Read more →

What if you knew Alzheimer’s was coming for you?

17 November 2017 - Simple blood tests may soon be able to deliver alarming news about your cognitive health. ...

Read more →

FDA unveils a streamlined path for the authorisation of tumour profiling tests alongside its latest product action

15 November 2017 - The U.S. FDA today authorised Memorial Sloan Kettering Cancer Center’s IMPACT (Integrated Mutation Profiling of Actionable Cancer ...

Read more →